Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 10/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8231022 | 0.84 | ACKR3 (0.46) | TBK1 | |
| SCHEMBL13003627 | 0.83 | CYP3A4 (0.49) | TBK1 | |
| SCHEMBL13060200 | 0.82 | ACKR3 (0.45) | TBK1 | |
| SCHEMBL12533226 | 0.81 | ACKR3 (0.43) | TBK1 | |
| SCHEMBL13390971 | 0.81 | ACKR3 (0.42) | TBK1 | |
| SCHEMBL8225788 | 0.80 | GSK3B (0.47) | TBK1 | |
| SCHEMBL12533228 | 0.80 | ACKR3 (0.42) | TBK1 | |
| SCHEMBL13003714 | 0.80 | MAPK1 (0.46) | MAPK1HTTSMN1; SMN2HPGDALOX15 | |
| SCHEMBL13060206 | 0.80 | POLB (0.42) | TBK1MAPK1HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL13060205 | 0.80 | MAPK1 (0.43) | TBK1MAPK1HTTALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7846946-B2 | Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists | SCHERING PLOUGH CORPORATION (US) | 2010-12-07 | — | — | US | disclosed |
| US-7846946-B2 | Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists | SCHERING PLOUGH CORPORATION (US) | 2010-12-07 | — | — | US | disclosed |
| US-7635705-B2 | treating allergy-induced airway responses, congestion, obesity, metabolic syndrome, alcoholic fatty liver disease, hepatic steatosis, nonalcoholic steatohepatitis, cirrhosis, hepatacellular carcinoma and cognition deficit disorders; histamine H3 antagonists | SCHERING CORPORATION (US) | 2009-12-22 | — | — | US | disclosed |
| US-7635705-B2 | treating allergy-induced airway responses, congestion, obesity, metabolic syndrome, alcoholic fatty liver disease, hepatic steatosis, nonalcoholic steatohepatitis, cirrhosis, hepatacellular carcinoma and cognition deficit disorders; histamine H3 antagonists | SCHERING CORPORATION (US) | 2009-12-22 | — | — | US | disclosed |
| US-20090286830-A1 | HETEROATOM-LINKED SUBSTITUTED PIPERIDINES AND DERIVATIVES THEREOF USEFUL AS HISTAMINE H3 ANTAGONISTS | SCHERING CORPORATION | 2009-11-19 | — | — | US | disclosed |
| US-20090286830-A1 | HETEROATOM-LINKED SUBSTITUTED PIPERIDINES AND DERIVATIVES THEREOF USEFUL AS HISTAMINE H3 ANTAGONISTS | SCHERING CORPORATION | 2009-11-19 | — | — | US | disclosed |
| WO-2007075555-A2 | COMBINATION OF AN H3 ANTAGONIST/INVERSE AGONIST AND AN APPETITE SUPPRESSANT | SCHERING CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | SCHERING CORPORATION | 2007-06-21 | — | — | US | disclosed |
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | SCHERING CORPORATION | 2007-06-21 | — | — | US | disclosed |
| US-20070015807-A1 | Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists | SCHERING CORPORATION | 2007-01-18 | — | — | US | disclosed |
| US-20070015807-A1 | Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists | SCHERING CORPORATION | 2007-01-18 | — | — | US | disclosed |
| WO-2007001975-A1 | PIPERIDINE DERIVATIVES USEFUL AS HISTAMINE H3 ANTAGONISTS | SCHERING CORPORATION (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | CNR2, GPR119, GLP1R | TBK1 2533/4885MAPK1 3216/4885HTT 267/4885 |
| US-20070015807-A1 | Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists | HRH3, HRH4, CHRM2 | TBK1 4090/4885MAPK1 2566/4885HTT 1945/4885 |
| US-20090286830-A1 | HETEROATOM-LINKED SUBSTITUTED PIPERIDINES AND DERIVATIVES THEREOF USEFUL AS HISTAMINE H3 ANTAGONISTS | HRH3, HRH4, CHRM2 | TBK1 4090/4885MAPK1 2566/4885HTT 1945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.